logo

Arqule Inc. (ARQL)



Trade ARQL now with
  Date
  Headline
6/17/2019 9:09:22 AM ArQule Announces Preliminary Results From Phase 1/2 Study Of Miransertib
3/7/2019 7:11:09 AM ArQule Q4 Net Loss $8.49 Mln Or $0.08/Shr Vs Loss Of $7.76 Mln Or $0.09/Shr Last Year
1/24/2019 7:04:40 AM ArQule: Basilea Enters Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer
12/19/2018 7:01:58 AM ArQule Says Selected For Inclusion In NASDAQ Biotechnology Index
12/3/2018 7:01:23 AM ArQule Announces Data From Phase 1 Study Of Reversible BTK Inhibitor, ARQ 531, In Relapsed/RHM
11/19/2018 7:00:53 AM ArQule To Present Clinical Data For ARQ 531 At 2018 ASH Annual Meeting
10/31/2018 7:03:44 AM ArQule Q3 Net Loss $5.62 Mln Or $0.05/Shr Vs Loss Of $6.67 Mln Or $0.09/Shr Last Year
10/19/2018 7:04:39 AM ArQule Presents Orphan Disease Clinical Data At ASHG 2018 Annual Meeting
9/13/2018 7:04:15 AM ArQule Says Miransertib Granted Fast Track Designation For Treatment Of PIK3CA-Related Overgrowth Spectrum
8/1/2018 7:04:27 AM ArQule Q2 EPS $0.05 Vs Loss $0.10 Last Year
7/11/2018 7:00:53 AM ArQule Prices Public Offering Of 11 Mln Common Shares At $5.50 Per Share